# A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

> **NCT01815684** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 26 (actual)

## Conditions studied

- Pharmacokinetics
- Pharmacodynamics
- Healthy Subjects
- Safety

## Interventions

- **DRUG:** ASP3652
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01815684
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2013-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01815684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01815684, "A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01815684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*